 | | Vol. 13.42 – 18 November, 2021 |
| |
|
|
| Investigators suggested RAB5A as a predictive biomarker for trastuzumab emtansine response and outlined proteins involved in endocytic trafficking as predictive biomarkers for antibody–drug conjugates.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors found that RGMA was downregulated in breast cancer (BC) tissues compared with non-tumorous breast tissues, particularly in metastatic BC samples, and that patients with low RGMA expression manifested a poorer prognosis.
[Oncogene] |
|
|
|
| To identify key immune players in the tumor microenvironment, scientists applied highly invasive MDA-MB-231 breast cancer cell lines to co-culture with human monocyte THP-1 cells and identified CXCL7 by cytokine array as one of the increasingly secreted cytokines by THP-1 cells.
[Cell Death & Disease] |
|
|
|
| The authors studied cell lines derived from two transgenic mammary tumors driven by human HER2 that showed different dynamics of HER2 status. A dynamic model of HER2 status could lead to the identification of new druggable targets to counteract the resistance to HER2-targeted therapy caused by HER2 loss.
[Oncogenesis] |
|
|
|
| In order to assess whether other genes implicated in NAD+ metabolism were synthetic lethal with BRCA1 or BRCA2 gene defects, scientists carried out a genetic screen, which identified a synthetic lethality between BRCA1 and genetic inhibition of either of two sirtuin enzymes.
[Communications Biology] |
|
|
|
| Investigators showed that high expression of dihydrolipoamide S-succinyltransferase (DLST), a tricarboxylic acid (TCA) cycle enzyme, predicted poor overall and recurrence-free survival among TNBC patients.
[Communications Biology] |
|
|
|
| Scientists explored the function of circular RNA nucleolar and coiled-body phosphoprotein 1 (circNOLC1) in cancer stem cells of breast cancer and the inhibitory impact of propofol on circNOLC1.
[Journal of Translational Medicine] |
|
|
|
| Researchers investigated the capacity of NCT-58, a rationally-synthesized C-terminal HSP90 inhibitor, to kill trastuzumab-resistant HER2-positive breast cancer stem-like cells.
[Cell Death Discovery] |
|
|
|
| Scientists used mammary tumors with in situ immunomodulation consisting of intratumoral injections of Flt3L to mobilize conventional type-1 dendritic cells (cDC1s), local irradiation to induce immunogenic tumor cell death, and TLR3/CD40 stimulation to activate cDC1s.
[Scientific Reports] |
|
|
|
| Breast cancer cells preferentially metastasize to bone. To study the bone-tumor paracrine influence, a tri-cellular 3-D vascularized breast cancer tissue model was engineered which comprised MDA-MB231, TNBCs, fibroblasts, and endothelial cells.
[Scientific Reports] |
|  |
|
|
|
| Investigators describe the current and upcoming therapeutic landscape of TNBC and discuss how an integrated view of the TNBC ecosystem can define different levels of risk and provide improved opportunities for tailoring treatment.
[Nature Reviews Clinical Oncology] |
|
|
|
| Genome-wide association studies coupled with large-scale replication and fine-scale mapping studies have identified more than 150 genomic regions that are associated with breast cancer risk. Scientists review efforts to translate these findings into a greater understanding of disease mechanisms.
[British Journal of Cancer] |
|
|
|
| The authors describe the biological effects of estrogen, progesterone, and their metabolites on the proliferation of breast cancer cells, based on relevant research and clinical trials, to improve our understanding of the biological functions of estrogen and progestogen.
[Cancer Biology & Medicine] |
|
|
|
|
| Daiichi Sankyo Company, Limited announced that the first patient was dosed in the global TROPION-Breast01 Phase III trial evaluating the efficacy and safety of datopotamab deruxtecan in patients with hormone receptor positive, HER2 negative inoperable or metastatic breast cancer.
[Daiichi Sankyo Company, Limited] |
|
|
|
| CytoDyn, Inc. announced that Health Canada authorized the emergency use of leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, for the treatment of a patient with metastatic triple-negative breast cancer.
[CytoDyn, Inc.] |
|
|
|
|
| December 1 – 10, 2021
Virtual |
|
|
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York City, New York, United States |
|
|
|
| | University of Bergen – Bergen, Norway |
|
|
|
| | University of Maryland School of Medicine – Baltimore, Maryland, United States |
|
|
|
| | Georgetown University School of Medicine – Washington, District of Columbia, United States |
|
|
|
| | City of Hope – Los Angeles, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
